Can Itopride Cause Drug-Induced Parkinsonism?
Itopride can theoretically cause drug-induced parkinsonism due to its dopamine D2 receptor antagonist mechanism, but the risk appears to be extremely low because of its minimal central nervous system penetration.
Understanding the Mechanism and Risk
Itopride is a prokinetic agent that works as a dopamine D2 receptor antagonist, similar to metoclopramide. Drug-induced parkinsonism occurs when antidopaminergic agents block D2 receptors in the nigrostriatal pathways, producing symptoms of bradykinesia, tremors, and rigidity 1. This is a well-established adverse effect of dopamine antagonists used for gastrointestinal disorders 2, 3.
However, itopride has a critical pharmacological difference: it has very low CNS penetration, which substantially reduces the risk of central nervous system-related side effects including drug-induced parkinsonism 4.
Clinical Evidence
The most compelling evidence comes from a 2025 case report where itopride was successfully used to treat gastroptosis in a patient with pre-existing Parkinson's disease without worsening the parkinsonian symptoms 4. This demonstrates that:
- Despite being a dopamine antagonist, itopride's minimal CNS penetration allows it to be used even in patients with established Parkinson's disease
- The peripheral selectivity of itopride provides gastrointestinal prokinetic effects without significant central dopaminergic blockade
Comparison with Other Prokinetics
When comparing itopride to other dopamine antagonists used for gastroparesis:
- Metoclopramide carries an FDA black box warning for tardive dyskinesia and is known to cause extrapyramidal symptoms including drug-induced parkinsonism 2, 3
- Domperidone has better CNS safety than metoclopramide and may be especially helpful for patients with neurologic movement disorders or Parkinson's disease 2
- Itopride appears to have the most favorable CNS safety profile among dopamine antagonist prokinetics
Clinical Recommendations
If you prescribe itopride:
- The risk of drug-induced parkinsonism is minimal but not zero
- Monitor patients for new-onset parkinsonian symptoms (bradykinesia, tremor, rigidity) during the first few weeks of treatment
- Itopride may be a safer alternative to metoclopramide in patients at higher risk for extrapyramidal side effects
- Consider itopride as a reasonable option even in patients with pre-existing Parkinson's disease when gastrointestinal prokinetic therapy is needed 4
Important Caveats
While the evidence suggests itopride is safer than other dopamine antagonists regarding CNS effects, the available data is limited. The 2026 multicenter study showed only 2% of patients experienced mild adverse effects overall, with no specific mention of parkinsonian symptoms 5. However, early diagnosis and rapid withdrawal of any dopaminergic antagonist improves the possibility of complete recovery if drug-induced parkinsonism does occur 1.
If parkinsonian symptoms develop, discontinue itopride immediately and reassess the patient within 4-8 weeks, as drug-induced parkinsonism typically improves after medication withdrawal, unlike progressive idiopathic Parkinson's disease 6.